Rhythm Pharmaceuticals and LG Chem Life Sciences Enter Agreement for Rhythm to Acquire Global Rights to Oral MC4R Agonist LB54640
— LB54640 has shown targeted effect on MC4 receptor without hyperpigmentation —
— Rhythm to advance LB54640 in two Phase 2 clinical trials —
Related news for (RYTM)
- Rhythm Pharmaceuticals Announces New Data Presentations on Patients with Acquired or Congenital Hypothalamic Obesity (N=35) Treated with Setmelanotide for up to Nine Months in French Early-access Program
- Rhythm Pharmaceuticals Reports First Quarter 2025 Financial Results and Business Update
- Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences
- Rhythm Pharmaceuticals to Report First Quarter 2025 Financial Results on Wednesday, May 7, 2025
- Rhythm Pharmaceuticals Announces Pivotal Phase 3 TRANSCEND Trial Meets Primary Endpoint with -19.8% Placebo-adjusted BMI Reduction in Patients (N=120) with Acquired Hypothalamic Obesity